AU2016238523A1 - Fused bicyclic compounds for the treatment of disease - Google Patents

Fused bicyclic compounds for the treatment of disease Download PDF

Info

Publication number
AU2016238523A1
AU2016238523A1 AU2016238523A AU2016238523A AU2016238523A1 AU 2016238523 A1 AU2016238523 A1 AU 2016238523A1 AU 2016238523 A AU2016238523 A AU 2016238523A AU 2016238523 A AU2016238523 A AU 2016238523A AU 2016238523 A1 AU2016238523 A1 AU 2016238523A1
Authority
AU
Australia
Prior art keywords
optionally substituted
compound
formula
hydrogen
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016238523A
Other languages
English (en)
Inventor
Raju Mohan
Benjamin Anthony PRATT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akarna Therapeutics Ltd
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of AU2016238523A1 publication Critical patent/AU2016238523A1/en
Priority to AU2020256301A priority Critical patent/AU2020256301A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2016238523A 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease Abandoned AU2016238523A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020256301A AU2020256301A1 (en) 2015-03-26 2020-10-12 Fused bicyclic compounds for the treatment of disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562138725P 2015-03-26 2015-03-26
US62/138,725 2015-03-26
PCT/IB2016/000606 WO2016151403A1 (en) 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020256301A Division AU2020256301A1 (en) 2015-03-26 2020-10-12 Fused bicyclic compounds for the treatment of disease

Publications (1)

Publication Number Publication Date
AU2016238523A1 true AU2016238523A1 (en) 2017-11-09

Family

ID=56072361

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016238523A Abandoned AU2016238523A1 (en) 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease
AU2020256301A Abandoned AU2020256301A1 (en) 2015-03-26 2020-10-12 Fused bicyclic compounds for the treatment of disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020256301A Abandoned AU2020256301A1 (en) 2015-03-26 2020-10-12 Fused bicyclic compounds for the treatment of disease

Country Status (16)

Country Link
US (4) US10421759B2 (cg-RX-API-DMAC10.html)
EP (2) EP3715348A1 (cg-RX-API-DMAC10.html)
JP (1) JP6843061B2 (cg-RX-API-DMAC10.html)
KR (1) KR20180003545A (cg-RX-API-DMAC10.html)
CN (1) CN107912042A (cg-RX-API-DMAC10.html)
AU (2) AU2016238523A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017020374A2 (cg-RX-API-DMAC10.html)
CA (1) CA2980394A1 (cg-RX-API-DMAC10.html)
CL (1) CL2017002405A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017010621A2 (cg-RX-API-DMAC10.html)
HK (1) HK1249756A1 (cg-RX-API-DMAC10.html)
IL (1) IL254572A0 (cg-RX-API-DMAC10.html)
MX (1) MX370897B (cg-RX-API-DMAC10.html)
RU (2) RU2021107054A (cg-RX-API-DMAC10.html)
SG (2) SG10201908881PA (cg-RX-API-DMAC10.html)
WO (1) WO2016151403A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021107054A (ru) * 2015-03-26 2021-03-31 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
JP2019520335A (ja) * 2016-05-25 2019-07-18 アカーナ・セラピューティクス・リミテッドＡｋａｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｔｄ． 疾患治療用の縮合二環式化合物
MX2018014024A (es) * 2016-05-25 2019-08-29 Akarna Therapeutics Ltd Terapias de combinación con moduladores del receptor x farnesoide (fxr).
BR112019025228A2 (pt) * 2017-06-02 2020-06-23 Akarna Therapeutics, Ltd. Compostos bicíclicos fundidos
CN108264474B (zh) * 2018-02-09 2019-10-25 浙江师范大学 一种色胺及其衍生物的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
WO2005009387A2 (en) * 2003-07-23 2005-02-03 X-Ceptor Therapeutics Inc. Azepine derivatives as pharmaceutical agents
EP1776112A4 (en) 2004-08-10 2009-11-25 Exelixis Inc HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
WO2007070796A1 (en) * 2005-12-15 2007-06-21 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
US20090131409A1 (en) * 2007-10-22 2009-05-21 Wyeth 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090137554A1 (en) 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
JP2012503654A (ja) * 2008-09-26 2012-02-09 ワイス・エルエルシー １，２，３，６−テトラヒドロアゼピノ［４，５−ｂ］インドール−５−カルボキシレート核内受容体阻害剤
CA2968434A1 (en) * 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
RU2741387C2 (ru) * 2014-12-22 2021-01-25 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
RU2021107054A (ru) * 2015-03-26 2021-03-31 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания

Also Published As

Publication number Publication date
WO2016151403A1 (en) 2016-09-29
MX370897B (es) 2020-01-09
JP2018510876A (ja) 2018-04-19
US20180118752A1 (en) 2018-05-03
EP3274350A1 (en) 2018-01-31
CL2017002405A1 (es) 2018-04-27
HK1249756A1 (zh) 2018-11-09
CA2980394A1 (en) 2016-09-29
SG11201707610PA (en) 2017-10-30
US10421759B2 (en) 2019-09-24
IL254572A0 (en) 2017-11-30
AU2020256301A1 (en) 2020-11-05
US20230002394A1 (en) 2023-01-05
CO2017010621A2 (es) 2018-01-31
RU2017137366A3 (cg-RX-API-DMAC10.html) 2019-07-17
RU2021107054A (ru) 2021-03-31
CN107912042A (zh) 2018-04-13
EP3715348A1 (en) 2020-09-30
MX2017012342A (es) 2018-06-11
RU2017137366A (ru) 2019-04-26
US20210214362A1 (en) 2021-07-15
JP6843061B2 (ja) 2021-03-17
SG10201908881PA (en) 2019-11-28
BR112017020374A2 (pt) 2018-06-05
KR20180003545A (ko) 2018-01-09
US20200079782A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
AU2020250270B2 (en) Fused bicyclic compounds for the treatment of disease
US10793577B2 (en) Fused bicyclic compounds for the treatment of disease
US20210214362A1 (en) Fused bicyclic compounds for the treatment of disease
CA3025326A1 (en) Fused bicyclic compounds for the treatment of disease
HK40049146A (en) Fused bicyclic compounds for the treatment of disease
HK1245795B (en) Fused bicyclic compounds for the treatment of disease
HK1244802B (en) Fused bicyclic compounds for the treatment of disease

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted